Ultragenyx Pharmaceutical (STU:UP0) Dividends per Share : €0.00 (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Ultragenyx Pharmaceutical Dividends per Share?

Ultragenyx Pharmaceutical's dividends per share for the three months ended in Mar. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Ultragenyx Pharmaceutical's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Ultragenyx Pharmaceutical Dividends per Share Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Dividends per Share Chart

Ultragenyx Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

Ultragenyx Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Ultragenyx Pharmaceutical's Dividends per Share

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ultragenyx Pharmaceutical's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Dividend Yield % falls into.

Ultragenyx Pharmaceutical Dividends per Share Calculation

Dividends paid to per common share.

Ultragenyx Pharmaceutical (STU:UP0) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Ultragenyx Pharmaceutical's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-1.892
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Ultragenyx Pharmaceutical Dividends per Share Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultragenyx Pharmaceutical (STU:UP0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (STU:UP0) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

RARE:USA RARE:Mexico

Address

60 Leveroni Court, Novato, CA, USA, 94949

Website

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (STU:UP0) Headlines

No Headlines